FOR IMMEDIATE RELEASE

June 12, 2014

AnGes MG, Inc.

AnGes Signs an Agreement with Quintiles for the Global Phase III Trial of Collategene®, a Gene Therapy Product for Critical Limb Ischemia

AnGes MG, Inc. (AnGes) announced today that the company has signed an agreement with Quintiles (Headquarters: North Carolina, USA, CEO: Tom Pike) to conduct the global phase III trial of "Collategene® (DNA plasmid with HGF gene)" in Critical Limb Ischemia (CLI).

AnGes selected Quintiles, world's largest provider of biopharmaceutical development and commercial outsourcing services, as the most suitable CRO to conduct the global clinical trial. AnGes and Quintiles signed a letter of intent in January 2014 and have worked together in preparations for the global phase III trial of Collategene®. AnGes is pleased to announce today that the final contract has been signed.

As already announced by AnGes on February 7, 2014, the trial will enroll approximately 500 patients with CLI and will be conducted at multiple sites in North America, Europe and South America. The first patient is expected to be dosed in the third quarter of 2014 (July-September). AnGes has completed the necessary procedures with the U.S. Food and Drug Administration (FDA) regarding the initiation of Phase III trial.

Ei Yamada, the President and CEO, AnGes, said, "The development of Collategene® as a treatment of CLI has been our core project since the company's establishment, and it is expected to become the mainstay of our future growth. I believe the global phase III trial of Collategene® will be conducted under a strong partnership with Quintiles, the world largest CRO and the expert in pharmaceutical development."

CLI is a serious condition in which poor blood circulation causes severe pains, ulcer, and necrosis which may ultimately lead to the amputation of a lower limb. Effective treatment is currently unavailable for patients who are ineligible for the existing treatments of revascularizations such as balloon-catheter treatment or bypass surgery. Collategene®, the gene therapy product, is believed to cure CLI with its innovative mechanism; injection of Hepatocyte Growth Factor (HGF) gene plasmid into the affected limb induces the growth and development of new blood vessels, and blood circulation can be restored as a result. In the

U.S., there are 500,000 CLI patients with the potential market estimated to be 5 billion dollars.

The effect of this event on AnGes's business performance for the fiscal term ending in December 2014 is included in the forecast published on the "Consolidated Financial Report for the Year Ended December 31, 2013" announced on February 7, 2014.

*1 CRO

CRO (Contract Research Organization) is an organization that provides supports to the development of pharmaceutical products on a contract basis by mainly performing clinical trial related services outsourced by pharmaceutical industries.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGesMG,Inc.
Corporate Communications
TEL:+81-3-5730-2480, FAX:+81-3-5730-2676
http://www.anges-mg.com
Email:info@anges-mg.com